Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 7, 2023; 29(9): 1395-1426
Published online Mar 7, 2023. doi: 10.3748/wjg.v29.i9.1395
Published online Mar 7, 2023. doi: 10.3748/wjg.v29.i9.1395
Figure 3 Mechanisms of resistance to targeted therapy and strategies to overcome resistance in colorectal cancer.
A: Resistance mechanisms; B: Strategies to overcome resistance. EGFR: Epidermal growth factor receptor; HER2: Human epidermal growth factor receptor 2; VEGF: Vascular endothelial growth factor; MEK: Mitogen-activated extracellular signal-regulated kinase; MAP2K1: Mitogen-Activated Protein Kinase 1; PI3KCA: Phosphoinositide 3-kinases catalytic subunit alpha; MAP2K1: Mitogen-activated protein kinase 1; HGF: Hepatocyte growth factor; MET: Mesenchymal epithelial transition; ERBB2: Erb-B2 Receptor Tyrosine Kinase 2; TME: Tumor microenvironment; FGF: Fibroblast growth factor; PDGF: Platelet-derived growth factor; PD-1: Programmed death-1; PD-L1: Programmed death ligand-1; CTLA-4: cytotoxic T lymphocyte-associated antigen 4.
- Citation: Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J Gastroenterol 2023; 29(9): 1395-1426
- URL: https://www.wjgnet.com/1007-9327/full/v29/i9/1395.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i9.1395